8-K: INVO Fertility Reshuffles Executive Team for Growth

INVO Fertility, Inc. announced a strategic executive leadership realignment, appointing Terah Krigsvold as CFO and Andrea Goren as Chief Business Officer and CEO of INVO Centers LLC to drive growth.

Summary

• Terah Krigsvold has been appointed Chief Financial Officer (CFO) of INVO Fertility, Inc., effective December 30, 2025.
• Ms. Krigsvold, who previously served as the Company's controller since December 3, 2020, will receive an annual salary of $250,000, with eligibility for bonus compensation up to 50% of her base salary and grants under the 2019 Stock Incentive Plan.
• Andrea Goren resigned as CFO, effective December 30, 2025, and was simultaneously appointed Chief Business Officer of INVO Fertility, Inc. and Chief Executive Officer of INVO Centers LLC, a wholly-owned subsidiary.
• Mr. Goren's resignation as CFO was not due to any disagreements with the Company on matters relating to its operations, policies, and practices.
• In his new role, Mr. Goren will focus on leading the execution of the Company's primary growth strategy, including acquisitions and new clinic launches, and will continue to manage legal functions and investor relations.
• Mr. Goren's base salary for his new roles is $250,000 per annum, effective January 1, 2026, with eligibility for bonus compensation up to 50% of his base salary and grants under the 2019 Stock Incentive Plan.
• The Company issued a press release on December 30, 2025, titled 'INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy' to announce these changes.

Sentiment

Score: 7

Explanation: The executive leadership changes are presented as a strategic and positive realignment aimed at strengthening the company's growth strategy and path to profitability. The promotion of an internal candidate to CFO ensures continuity, while the former CFO's move to a dedicated business development role leverages his extensive M&A experience. This indicates proactive management and a clear focus on future expansion.

Positives

• Strategic realignment of executive leadership is designed to strengthen the Company's ability to execute its growth strategy and reach profitability.
• Terah Krigsvold's promotion to CFO from controller ensures continuity and places financial and accounting functions in experienced hands, given her tenure since December 2020.
• Andrea Goren's new role as Chief Business Officer and CEO of INVO Centers LLC leverages his extensive experience (30+ years, approximately $1 billion in financing and acquisition transactions) to focus specifically on growth, acquisitions, and new clinic launches.
• Mr. Goren will continue to manage legal functions and support investor and shareholder activities, retaining his expertise within the Company.

Risks

• Forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond the Company's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements.
• Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the Company's filings at www.sec.gov.

Future Outlook

The Company aims to grow its presence in the fertility sector, execute its plan to grow the business, and reach profitability, primarily through acquisitions and new clinic launches. It also continues to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics.

Management Comments

• "As we continue to grow our presence in the fertility sector and based on Terah and Andrea's commitment, hard work and growth over the past five years, this realignment of roles strengthens our ability to execute our plan to grow the business and reach profitability." Steve Shum, CEO.
• "I have worked with Terah for the past seven years and am thrilled at the progress she has demonstrated over that time. This promotion is very well deserved and ensures continuity, as well as keeping our finance and accounting functions in a strong pair of hands." Steve Shum, CEO.
• "With this change, Andrea is now able to focus more of his time on leading the execution of our primary growth strategy, acquisitions, and, in due course, new clinic launches." Steve Shum, CEO.
• "Andrea has worked on approximately $1 billion of financing and acquisition transactions in his career and is ideally suited to manage the negotiations and complex legal and diligence aspects of our acquisition and new clinic efforts." Steve Shum, CEO.

Industry Context

The announcement reflects a strategic move within the healthcare fertility sector, where companies are expanding access to assisted reproductive technology (ART) care. INVO Fertility's focus on building, acquiring, and operating fertility clinics, including those utilizing its INVOcell medical device, positions it within a growing market for fertility services. The realignment aims to enhance the company's ability to compete and grow through acquisitions and new clinic development, a common strategy in consolidating or expanding healthcare markets.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact from a strengthened executive team focused on growth and profitability, which could lead to increased shareholder value.
• Employees: Continuity in the finance department with an internal promotion; strategic focus on growth could create new opportunities within the Company.
• Customers: Enhanced focus on clinic expansion and accessibility to ART care could benefit patients seeking fertility treatments.
• Management: Clearer roles and responsibilities, with specific focus areas for key executives to drive strategic objectives.

Next Steps

• Execute the plan to grow the business and reach profitability.
• Focus on acquisitions and new clinic launches.
• Continue the sale and distribution of INVOcell to third-party owned and operated fertility clinics.

Key Dates

Recommendation

The filing details a strategic executive leadership realignment aimed at strengthening the company's growth strategy and path to profitability. While the changes appear positive and logical, particularly leveraging Andrea Goren's M&A experience for acquisitions and new clinic launches, the filing does not provide immediate financial results or new guidance to warrant a 'buy' or 'sell' recommendation. It's a structural change with a long-term strategic intent. Investors should hold and monitor the execution of this growth strategy and subsequent financial performance.

Keywords

INVO Fertility, IVF, fertility clinics, CFO appointment, Chief Business Officer, executive leadership, corporate governance, growth strategy, Nasdaq: IVF, Terah Krigsvold, Andrea Goren, INVO Centers LLC, SEC filing, 8-K